R
RenovoRx, Inc. (RNXT)
NCM – Real Time Price. Currency in USD
0.87
+0.02 (2.68%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
0.87
+0.02 (2.68%)
At close: May 12, 2026, 4:00 PM EDT
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
| Name | Position |
|---|---|
| Dr. Ramtin Agah M.D. | Founder, Executive Chairman & Chief Medical Officer |
| Mr. Mark Voll | CFO & Principal Accounting Officer |
| Mr. Robert Strasser | Vice President of Operations and R&D |
| Mr. Ryan Witt | Senior VP and Head of Corporate Strategy & Partnerships |
| Mr. Shaun R. Bagai | CEO, Secretary & Director |
| Ms. Leesa Gentry | Chief Clinical Officer |
| Date | Type | Document |
|---|---|---|
| 2026-04-30 | DEF 14A | formdef14a.htm |
| 2026-04-16 | S-3 | forms-3.htm |
| 2026-04-09 | D | |
| 2026-03-31 | S-8 | forms-8.htm |
| 2026-03-30 | 8-K | form8-k.htm |
| 2026-03-30 | 10-K | rnxt-20251231.htm |
| 2026-03-27 | 8-K | form8-k.htm |
| 2026-03-23 | 8-K | form8-k.htm |
| 2026-02-06 | 8-K | form8-k.htm |
| 2026-01-02 | 8-K | form8-k.htm |